Literature DB >> 7609941

Visual acuity changes throughout adulthood in normal, healthy eyes: seeing beyond 6/6.

D B Elliott1, K C Yang, D Whitaker.   

Abstract

There are many useful longitudinal and cross-sectional epidemiological studies of how visual acuity (VA) deteriorates with age. However, few studies have evaluated age-related VA changes in normal, healthy eyes. Data from three previous studies that included VA measurements taken with logMAR charts from subjects with normal, healthy eyes were collated and additional data from 42 subjects were added. This provided VA results from 223 subjects (age range 18 to 80 years). Mean logMAR VA improved from -0.13 (Snellen equivalent 6/4.5) in 18- to 24-year-olds to -0.16 (Snellen 6/4(-1)) in 25- to 29-year-olds and then gradually became worse with age to a mean value of -0.02 (Snellen 6/6+1) for subjects over 75 years of age. The inadequacy of 6/6 as a norm value of VA is illustrated. The data show VA levels far superior to the data from the standard references of Pitts (1982) and Weale. (1975, 82) We suggest that this is because we used logMAR charts (providing nontruncated data), the subject's optimal refractive correction (rather than habitual) and strict exclusion criteria ensuring that only subjects with normal, healthy eyes were recruited for the studies.

Entities:  

Mesh:

Year:  1995        PMID: 7609941     DOI: 10.1097/00006324-199503000-00006

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  55 in total

1.  Policy statements adopted by the Governing Council of the American Public Health Association, November 15, 2000.

Authors: 
Journal:  Am J Public Health       Date:  2001-03       Impact factor: 9.308

2.  Metrics of retinal image quality predict visual performance in eyes with 20/17 or better visual acuity.

Authors:  Raymond A Applegate; Jason D Marsack; Larry N Thibos
Journal:  Optom Vis Sci       Date:  2006-09       Impact factor: 1.973

3.  Impact of Zernike-fit error on simulated high- and low-contrast acuity in keratoconus: implications for using Zernike-based corrections.

Authors:  Jason D Marsack; Konrad Pesudovs; Edwin J Sarver; Raymond A Applegate
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  2006-04       Impact factor: 2.129

4.  Why preoperative acuity predicts postoperative acuity in wavefront-guided LASIK.

Authors:  Michelle T Aaron; Raymond A Applegate; Jason Porter; Larry N Thibos; Steve C Schallhorn; Tyson J Brunstetter; David J Tanzer
Journal:  Optom Vis Sci       Date:  2010-11       Impact factor: 1.973

5.  Brief Report: Vision in Children with Autism Spectrum Disorder: What Should Clinicians Expect?

Authors:  Pamela M Anketell; Kathryn J Saunders; Stephen M Gallagher; Clare Bailey; Julie-Anne Little
Journal:  J Autism Dev Disord       Date:  2015-09

6.  The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

Authors:  Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

7.  Normative best-corrected values of the visual image quality metric VSX as a function of age and pupil size.

Authors:  Gareth D Hastings; Jason D Marsack; Larry N Thibos; Raymond A Applegate
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  2018-05-01       Impact factor: 2.129

8.  Template-based correction of high-order aberration in keratoconus.

Authors:  Jason D Marsack; Jos J Rozema; Carina Koppen; Marie-Jose Tassignon; Raymond A Applegate
Journal:  Optom Vis Sci       Date:  2013-04       Impact factor: 1.973

9.  Do patients with age related maculopathy and cataract benefit from cataract surgery?

Authors:  G N Shuttleworth; E A Luhishi; R A Harrad
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

10.  Performance of wavefront-guided soft lenses in three keratoconus subjects.

Authors:  Jason D Marsack; Katrina E Parker; Raymond A Applegate
Journal:  Optom Vis Sci       Date:  2008-12       Impact factor: 1.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.